# Sulindac and Epirubicin in Treating Patients With Metastatic Malignant Melanoma

> **NCT00755976** · PHASE2 · COMPLETED · sponsor: **Cancer Trials Ireland** · enrollment: 32 (actual)

## Conditions studied

- Melanoma (Skin)

## Interventions

- **DRUG:** epirubicin hydrochloride
- **DRUG:** sulindac
- **OTHER:** immunologic technique

## Key facts

- **NCT ID:** NCT00755976
- **Lead sponsor:** Cancer Trials Ireland
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-08
- **Primary completion:** 2010-05
- **Final completion:** 2010-05
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2014-12-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00755976

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00755976, "Sulindac and Epirubicin in Treating Patients With Metastatic Malignant Melanoma". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00755976. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*